Endomysial Antibody IgA Profile #5099
Identify individuals who may have gluten sensitivity
NeuroScience, Inc. offers two profiles for gluten sensitivity and celiac testing
- Gluten Sensitivity Screen Profile #5056
- Endomysial Antibody IgA Profile #5099
Gluten Sensitivity
The term “gluten sensitivity” has been used to refer to a variety of clinical complaints caused by ingestion of gluten. The most commonly known gluten sensitivity is Celiac disease or gluten sensitive enteropathy (GSE). GSE is an autoimmune disease of the small intestines whereby the ingestion of gluten results in inflammation and loss of villus structure in individuals with the genetic predisposition. A second type of gluten sensitivity is known as gluten sensitivity without enteropathy. This type of sensitivity also involves an inappropriate immune response to gluten but can occur in any individual. Gluten sensitivity without enteropathy is induced mainly by enhanced intestinal permeability due to infection, stress, or chemical injuries. In both types of gluten sensitivity, the immune system over-reacts to the presence of gluten resulting in the production of antibodies to both gliadin and tissue transglutaminase.
Gluten Sensitivity Screen
NeuroScience, Inc.’s serum Gluten Sensitivity Screen (5056) assesses total IgA and antibody levels to gliadin and tissue transglutaminase. Serum used for the Gluten Sensitivity Screen may also be used for the Gluten Autoimmunity Profile (5057).
Summary
The consumption of gluten may trigger gluten sensitivities with or without enteropathy. The presence of gluten sensitivity in general can be assessed through either saliva or serum. If cross-reactive antibodies are produced, damage may occur to other organ systems resulting in the presentation of a variety of clinical symptoms which are not typically associated with gastrointestinal disorders.
Endomysial Antibody IgA Profile #5099
Circulating IgA endomysial (EMA) antibodies are present in 70% to 80% of patients with dermatitis herpetiformis or celiac disease, and in nearly all such patients who have high grade gluten-sensitive enteropathy and are not adhering to a gluten-free diet. The fnding of IgA-EMA is highly specifc for dermatitis herpetiformis or celiac disease.
In screening for celiac disease, IgA-EMA generally have a higher positive predictive value than IgA gliadin autoantibodies. Also, tissue transglutaminase results may be falsely positive in patients with type 1 diabetes and other autoimmune disorders. For these reasons, a positive IgA-EMA result may be used for confrmatory evidence of celiac disease in conjunction with analysis of results from the Gluten Sensitivity Screen profle #5056.
This profile includes the following test:
Specimen Type: Single serum collection
Specimen Requirement: One tiger top tube - 2 mL
|